Entropy's TRP-8803 psilocin infusions sustain improvements in treatment-resistant binge eating disorder for three months

Entropy Neurodynamics reports that two intravenous infusions of TRP-8803, an experimental formulation of psilocin, sustained clinically meaningful improvements in six patients with treatment-resistant binge eating disorder for 12 weeks after treatment. All six maintained improvement, while three reported no binge-eating episodes during the 84-day follow-up, which the company classified as full clinical remission. Weekly episodes remained 73% below the pretreatment baseline, close to the 74% reduction measured at four weeks. Anxiety fell 50%, depression 42%, and quality of life improved 61%, while clinician-rated global improvement increased from 33% at four weeks to 44% at 12 weeks. The findings are early and limited by the very small, company-reported Phase 2 Cohort 1 sample. Treatment sessions produced intense psychedelic effects, and preliminary EEG analysis found increased complexity and reduced alpha activity. Cohort 2 will test shorter infusions, with topline results expected in late 2026.